GlaxoSmithKline Pharmaceuticals Receives TDS Demand Order
GlaxoSmithKline Pharmaceuticals Limited has received a Final Order from the TDS Authority, INT Tax Circle 2(3)(2), imposing a TDS Demand Liability of Rs 2.01 Crores. The order, dated March 31, 2026, relates to a default under Section 201 for the assessment year 2020-2021.The TDS demand includes Rs 1.11 Crores in TDS and Rs 0.90 Crores in interest.
According to a filing, the company is contesting the assessment order and intends to file an appeal before the appellate authority. Management stated that the order is not expected to have an impact on the company’s financial statements.
| Particulars | Details |
|---|---|
| Authority | TDS Authority - INT Tax Circle 2(3)(2) |
| Nature of Action | Demand Liability under TDS default u/s 201 |
| Demand Amount | Rs 2.01 Crore (TDS Rs 1.11 Cr + Interest Rs 0.90 Cr) |
| Assessment Year | 2020-2021 |
| Date of Order | March 31, 2026 |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.